Crucial amino acid residues of mouse CD1d for glycolipid ligand presentation to Vα14NKT cells

被引:42
|
作者
Kamada, N
Iijima, H
Kimura, K
Harada, M
Shimizu, E
Motohashi, S
Kawano, T
Shinkai, H
Nakayama, T
Sakai, T
Brossay, L
Kronenberg, M
Taniguchi, M
机构
[1] Chiba Univ, Grad Sch Med, CREST, Chuo Ku, Chiba 2608670, Japan
[2] Chiba Univ, Grad Sch Med, Dept Mol Immunol, Chuo Ku, Chiba 2608670, Japan
[3] Chiba Univ, Sch Med, Dept Dermatol, Chuo Ku, Chiba 2608670, Japan
[4] Kirin Brewery Co Ltd, Pharmaceut Res Lab, Gunma 37012, Japan
[5] La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA
关键词
alpha-galactosylceramide; NKT cell receptor; docking modeling;
D O I
10.1093/intimm/13.7.853
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A novel lymphocyte, NKT cells bearing an invariant V(alpha)14 antigen receptor, specifically recognizes alpha -galactosylceramide (alpha -GalCer) exclusively presented by mouse CD1d (mCD1d). However, the precise molecular interaction remains unclear. For the basis of functional analyses, a docking model of alpha -GalCer with the crystal structure of mCD1d was constructed. Possible residues involved in the alpha -GalCer-mCD1d interaction were found to be Arg79, Glu83 and Asp80 for carbohydrate recognition, and Asp153 for interaction with the amide group on the fatty acyl chain. The alpha -GaLCer-presenting ability of various transfectants expressing mutant mCD1d was completely abrogated it a single amino acid mutation was induced at positions 79, 80, 83 or 153, suggesting that the polar amino acids above the F ' pocket are crucial for alpha -GalCer presentation to activate V alpha 14 NKT cells. The possibility that Glu83 is a contact site for the NKT cell receptor is also discussed.
引用
收藏
页码:853 / 861
页数:9
相关论文
共 50 条
  • [1] Regulation of Vα14 NKT cell-mediated cytotoxicity by a glycolipid ligand/CD1d complex on target cells
    Harada, M
    Kamada, N
    Kronenberg, M
    Nakayama, T
    Taniguchi, M
    FASEB JOURNAL, 2001, 15 (05): : A1025 - A1025
  • [2] Glycolipid antigen-presentation by CD1d and mechanism of NKT cell activation
    Zajonc, Dirk
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [3] CD1d antigen presentation: treats for NKT cells
    Dale I Godfrey
    James McCluskey
    Jamie Rossjohn
    Nature Immunology, 2005, 6 : 754 - 756
  • [4] CD1d antigen presentation: treats for NKT cells
    Godfrey, DI
    McCluskey, J
    Rossjohn, J
    NATURE IMMUNOLOGY, 2005, 6 (08) : 754 - 756
  • [5] The Vα14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex
    Sidobre, S
    Naidenko, OV
    Sim, BC
    Gascoigne, NRJ
    Garcia, KC
    Kronenberg, M
    JOURNAL OF IMMUNOLOGY, 2002, 169 (03): : 1340 - 1348
  • [6] Glycolipid antigen processing for presentation by CD1d molecules
    Prigozy, TI
    Naidenko, O
    Qasba, P
    Elewaut, D
    Brossay, L
    Khurana, A
    Natori, T
    Koezuka, Y
    Kulkarni, A
    Kronenberg, M
    SCIENCE, 2001, 291 (5504) : 664 - 667
  • [7] Cutting edge:: Influence of the TCR Vβ domain on the avidity of CD1d:α-galactosylceramide binding by invariant Vα14 NKT cells
    Schümann, J
    Voyle, RB
    Wei, BY
    MacDonald, HR
    JOURNAL OF IMMUNOLOGY, 2003, 170 (12): : 5815 - 5819
  • [8] CD4+ Vα14NKT cells play a crucial role in an early stage of protective immunity against infection with Leishmania major
    Ishikawa, H
    Hisaeda, H
    Taniguchi, M
    Nakayama, T
    Sakai, T
    Maekawa, Y
    Nakano, Y
    Zhang, MX
    Zhang, TQ
    Nishitani, M
    Takashima, M
    Himeno, K
    INTERNATIONAL IMMUNOLOGY, 2000, 12 (09) : 1267 - 1274
  • [9] Function of human invariant NKT cells is regulated by the distinct binding kinetics of their TCRs to the CD1d/glycolipid complexes
    Matulis, G.
    Jacobsen, B.
    Villiger, P. M.
    Gadola, S. D.
    JOINT BONE SPINE, 2007, 74 (02) : 216 - 216
  • [10] MHC class II expression functionally enhances CD1d presentation of an exogenous glycolipid by accelerating CD1d internalization
    Chen, Xiuxu
    Keaton, Jason M.
    Besra, Gurdyal S.
    Gumperz, Jenny E.
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S56 - S56